Protective Signatures of Roselle (*Hibiscus sabdariffa* L.) Calyx Fractions against *Staphylococcus aureus* in *Drosophila* Infection Model

Firzan Nainu[1*], M. Natsir Djide[1], Subehan[1], Sartini[1], Tri Puspita Roska[1], Emil Salim[2,3], Takayuki Kuraishi[3]

[1]Faculty of Pharmacy, Universitas Hasanuddin, Makassar, Indonesia
[2]Faculty of Pharmacy, Universitas Sumatera Utara, Medan, Indonesia
[3]Faculty of Pharmacy, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Ishikawa, Japan

ARTICLE INFO

ABSTRACT

The rise of antibiotic-resistant *Staphylococcus aureus*-related clinical cases is an alarming chronicle for global communities. This research was conducted to examine the antistaphylococcal effect of roselle (*Hibiscus sabdariffa* L.) calyx fractions in the *Drosophila* model. In the infection experiment, wild-type and immunodeficient *Drosophila* were pricked with *S. aureus* and subsequently subjected to fly survivorship and colony-forming assays, in the presence or absence of roselle calyx fractions. The Involvement of immune stimulation in the host antibacterial protection was assessed *in vitro* using cell-based luciferase reporter assay and *in vivo* using RT-qPCR analysis on adult flies. A declining rate of fly survivorship and augmentation of bacterial growth were observable in *S. aureus*-infected wild-type flies but subject to improvement in the presence of roselle calyx fractions. Cell-based analysis revealed the absence of host immune stimulation via *Drosophila* Toll pathway and roselle calyx fractions-treated immune-deficient flies lacking for components in the Toll pathway were protected from infection-induced early death phenotype and harbored reduced number of *S. aureus* colonies. Overall, our data confirmed the *in vivo* anti-staphylococcal activity of roselle calyx fractions in *Drosophila* infection model and such protective signature was devoid of host immune stimulation.

1. Introduction

The escalation of worldwide infection cases caused by antibiotic-resistant bacteria presents a serious challenge to the health of global population (Levy and Marshall 2004; Gelband *et al.* 2015). An example of such pathogenic bacteria is *Staphylococcus aureus* (WHO 2017), especially the strain so called Methicillin-resistant *S. aureus* (MRSA) (Hassoun *et al.* 2017). Current guideline in the treatment of *S. aureus* infection primarily relies on the application of first-line β-lactam antibiotics, such as selected penicillin and cephalosporins derivatives, and in the MRSA-related infections, vancomycin remains the first-choice arsenal to be used in the treatment (Tong *et al.* 2015). Unfortunately, the increasing number of *S. aureus* strains that are resistant to available antibiotics has been widely reported (Tong *et al.* 2015; Hassoun *et al.* 2017; WHO 2017), critically emphasizes the need

to discover new antibacterial agents that are effective to treat the pathogenic mutant strains of *S. aureus*.

At present, directed exploration of natural resources is the main pathway to discover new entities of antibacterial agents with a possible novel mode of action (Lewis 2013; Wright 2014). Of many potential sources to find antibacterial compounds with such characteristics, roselle (*Hibiscus sabdariffa* L.) calyx is perhaps one of great choices. Roselle calyx extract has been reported to exert antistaphylococcal activity both *in vitro* (Liu *et al.* 2005; Alaga *et al.* 2014) and *in vivo* (Ahsan *et al.* 2019). With such promising results in hand, it seems sensible to advance research into the next level: step-by-step assessment on the nature of antibacterial compound(s) contained in the roselle calyx extract.

In effort to discover new antibacterial agent(s) from natural resources, the use of inexpensive and practical *in vivo* model organism become an important subject to consider. In accordance with that, we recently demonstrated the use of fruit fly or vinegar fly (*Drosophila melanogaster*) infection model to assess the

* Corresponding Author
  E-mail Address: firzannainu@unhas.ac.id

anti-staphylococcal activity of crude extracts prepared from green algae *Ulva reticulata* (Nainu *et al.* 2018) and roselle (*Hibiscus sabdariffa* L.) calyx (Ahsan *et al.* 2019). While it is evident that the fruit fly model of infection is easy-to-use and suitable for rapid *in vivo* screening, this particular insect has been reported as a suitable host for *Staphylococcus aureus* (Needham *et al.* 2004; Garcia-Lara *et al.* 2005; Wu *et al.* 2012; Nainu *et al.* 2018). In addition, the application of cost-effective yet robust techniques available in fruit fly has been central attention to the promising use of such model system in developing countries with limited access to advanced research facilities. Taking those advantages into account, here we presented the *in vivo* anti-staphylococcal activity of fractions prepared from ethanolic extract of roselle (*H. sabdariffa* L.) calyx using our established *Drosophila* infection model.

2. Materials and Methods

2.1. Bacterial Strains and Fly Stocks

Bacterial infection experiments were carried out using a 24-h old culture of *S. aureus* ATCC 29213 (collection of microbiology laboratory, Faculty of Pharmacy, Hasanuddin University). The bacterial inoculum was collected, washed carefully with phosphate buffered saline (PBS), diluted equal to 0.5 McFarland density, and suspended in PBS prior to use. The following lines of *D. melanogaster* were used as *in vivo* model organisms: w1118 as wildtype (background) control and *psh[1];;modSP[KO]* as the immunodeficient fly line with diminished activity of Toll pathway. Both fly lines were subjected to standard maintenance in cornmeal-agar medium at 25°C.

2.2. Preparation of Roselle Extract and Fractions

Roselle (*Hibiscus sabdariffa* L.) calyces were collected from Makassar, South Sulawesi, Indonesia and processed in a wet and dry sortation methods. Dried samples were subsequently subjected to a maceration procedure using 70% ethanol for 1 x 24 hours and then re-macerated for 1 x 24 hours, as described in (Ahsan *et al.* 2019) with slight modifications. All resulting filtrates were pooled and processed in a rotary evaporator to produce extract with proper thickness. The resulting extract was subsequently subjected to the fractionation process using water: ethyl acetate mixture (1:1). Ethanolic extract of roselle calyces and its fractionated preparations were freeze-dried and used as samples in this study.

2.3. Fly Infection, Survival Assay and Bacterial Growth Analysis

Infection experiment was performed on the thorax of male *D. melanogaster* by using the pricking method,

as described previously (Nainu *et al.* 2018; Ahsan *et al.* 2019; Nainu *et al.* 2019). Briefly, 4-7 days old of adult male fruit flies (30 flies per group of treatment) were pricked using a tungsten fine needle that had been previously dipped in the *S. aureus* culture (100-fold dilution of 0.5 McFarland density). All pricked flies were maintained at 29°C and subjected to either assessment on fly survivorship or bacterial growth analysis using colony-forming assay as described previously (Nainu *et al.* 2018; Ahsan *et al.* 2019; Nainu *et al.* 2019). In the assessment of fly survival during infection, *S. aureus*-pricked flies were maintained in the presence or absence of roselle fractions or 200 µg/ml tetracycline as positive control and the number of survived/dead flies in each group was recorded twice in a day during the course of the experiment. For the assessment of bacterial growth during infection, *S. aureus*-pricked flies were maintained in a similar fashion as in the fly survival assay and at a designated time, five live flies were collected and manually squashed in PBS solution using a micro pestle to produce a fly lysate. Homogenates prepared from each group were serially diluted and cultured on Vogel-Johnson agar medium at 37°C for 1 x 24 hours. The number of bacterial colonies found on the Vogel-Johnson agar plate after incubation is expressed as CFU/ml. In all fly survival and colony-forming assay experiments, groups of PBS-pricked flies were used as controls.

2.4. *In vitro* Assessment on Cell Viability and Immunostimulation Potency

Cell viability and immunostimulation potency were assessed using cell-based reporter assay system, as described previously (Kanoh *et al.* 2015). Briefly, Drs-Luc-DL1 *Drosophila* cell line was incubated in the presence of tested samples at six different concentrations starting from 0.1 ppm to 100 ppm. Drs-Luc-DL1 *Drosophila* cells were tested for the viability upon incubation with different samples' concentrations for 12 hours at 25°C using CellTiter®-Glo Luminescent Cell Viability Assay (Promega) according to the manufacturer's protocol. Using the same experimental layout, Drs-Luc-DL1 *Drosophila* cells were examined for the Drosomycin stimulation potency using ONE-Glo Luciferase Assay System (Promega) according to the manufacturer's protocol.

2.5. Antimicrobial Peptide (AMP) Expression Analysis

Analysis on the expression of Drosomycin, an endogenous antimicrobial peptide produced by *Drosophila* in response to Gram-positive bacterial infection, was carried out using total RNA prepared from five *w1118* fly line in each experimental group at

50 hours post-inoculation with *S. aureus*. The collected *Drosophila* were homogenized in the *Treff tube* and subsequently processed using SV Total RNA Isolation System (Promega) as per manufacturer's instruction. Assessment on the level of *Drosomycin (Drs)* was carried out based on the reverse transcriptase (RT)-qPCR method using a pair of *Drs* primer. The sequence of *Drs* forward (F) and *Drs* reverse (R) were as follows: (*Drs*-F) 5'-CGTGAGAACCTTTTCCAATATGATG-3' and (*Drs*-R) 5'-TCCCAGGACCACCAGCAT-3'. All RT-qPCR reactions were held in a 20 µl volume using GoTaq® 1-Step RT-qPCR System (Promega), according to the manufacturer's protocol. The following RT-qPCR profile was carried out in a Rotor-Gene Q thermal cycler (Qiagen, Germany): reverse transcription step at 37°C for 15 mins, denaturation step at 95°C for 10 mins, and 40 cyclic repeats of 95°C for 10 secs and 60°C for 30 secs, and final extension step at 72°C for 30 secs. The expression level of host reference gene, ribosomal protein *rp49*, was assessed in each run using a pair of *rp49* primer and using the same RT-qPCR protocol as above. The sequence of *rp49* forward (F) primer and *rp49* reverse (R) primer were as follows: (*rp49*-F) 5'-GACGCTTCAAGGGACAGTATCTG-3' and (*rp49*-R) 5'-AAACGCGGTTCTGCATGAG-3'. The relative expression of *Drs* to *rp49* was analyzed using qGENE software (version 2.0.3.2) and the result was further subjected to statistical analysis. To verify the specificity of primers used in our RT-qPCR experiments, standard melt curve analysis was performed in each run.

2.6. Data Processing, Graph Preparation, and Statistical Analysis

All data, obtained from at least three independent experiments, were statistically processed using GraphPad Prism® 8. Data on fly survivorship were constructed as a Kaplan-Meier graph and statistically analyzed using log-rank approach. Data on bacterial growth, cell viability, immune stimulation potency, and *Drosomycin* mRNA level were shown as bar graphs and subjected to statistical analysis using one-way ANOVA. All data presented in this study are shown as mean ± S.D and p values of less than 0.05 were considered as significant.

3. Results

3.1. Dose-dependent Toxicity of Roselle Fractions in Cell Culture and Adult of *Drosophila melanogaster*

In this study, we investigated the antistaphylococcal effect of water and ethyl acetate fractions, or simply abbreviated as WFR and EAFR respectively, prepared from ethanolic extract of roselle calyx using our established *Drosophila*-based *in vivo* approach. As a start, we prepared WFR and EAFR from the ethanolic extract of roselle calyces and subsequently performed cell viability assay and fly survival assay to determine the toxicity as well as an appropriate concentration of WFR and EAFR to be used in the further experiments. As shown in Figure 1a, the viability of *Drosophila* cells was negatively affected by both samples at high concentrations (250 ppm) but not at the lower concentrations tested in the experiments. In accordance to that, the survival of adult male flies of *w*[1118] (Figure 1b) and *psh[1];;modSP[KO]* immunodeficient mutant line (Figure 1c) were not affected upon ingestion of either WFR or EAFR at concentrations up to 2% w/w. However, the survivals of both fly lines were adversely affected once maintained in foods containing each fractionated roselle samples at higher concentration (8% w/w). Results obtained from both *in vitro* and *in vivo* experiments clearly suggested the dose-dependent lethal effect of roselle fractions used in this study. To rule out such possible toxic influence, we used WFR and EAFR at a concentration ranging from 100 to 0.1 ppm and at concentration of 0.5% and 2% (w/w) in further *in vitro* and *in vivo* experiments, respectively.

3.2. Augmentation of Host Survival Rate by Roselle Fractions During Bacterial Infection

We previously reported the antibacterial activity of roselle calyx crude extract against Gram-positive *S. aureus* in *D. melanogaster*. However, the nature of the antibacterial compounds remains unidentified. To provide better insight, we carried out similar *in vivo* fly survival and CFU assays, in addition to an *in vitro* approach firstly performed in this study, using WFR and EAFR, fractions prepared from roselle calyx extract. We found that the survival of adult *D. melanogaster w*[1118] was rapidly declined under *S. aureus* infection condition and such trend was subject for improvement by the use of either antibiotic (as positive control) or the crude extract of roselle calyx (5%). Treatments of *S. aureus*-infected *w*[1118] with WFR or EAFR at a concentration of 2%, but not at 0.5%, were sufficient to reduce flies' mortality (Figure 2a), suggesting the *in vivo* anti-staphylococcal action of roselle fractions, WFR and EAFR, at a suitable concentration.

3.3. Inhibition of Bacterial Growth by Roselle Fractions

Augmentation of flies' mortality during *S. aureus* infection was reported to be linked with amplified bacterial load. Hence, the inhibition of bacterial proliferation, either by the use of antibiotics or crude plant extracts, has been shown to enhance the survivorship of infected *Drosophila*. With this in mind,

Figure 1. Dose-dependent toxicity of roselle fractions in *Drosophila*. (a) The incorporation of either WFR or EAFR in the cell media reduced the viability of Drs-Luc-DL1 cells in a concentration-dependent manner. (b and c) Similarly, ingestion of food-containing either WFR or EAFR decreased the survivorship of flies in a manner dependent on samples' concentration. Adult 4-7 days old male w^{1118} (b) and *psh[1];;modSP[KO]* (c) were maintained at 25°C in fly food containing samples at three different concentrations (0.5, 2, and 8%). The number of survived and dead flies were recorded daily and fly survivorship was analysed using a Kaplan-Meier-Log Rank approach. EER: ethanolic extract of roselle calyx, WFR: water fractions of rosella calyx extract, EAFR: ethyl acetate fractions of rosella calyx extract

we carried out CFU assays to confirm whether protection seen in both WFR-treated and EAFR-treated *S. aureus*-infected flies (Figure 2a) was the result of bacterial growth inhibition. Indeed, we noticed that continuous treatment of infected *Drosophila* with either 2% WFR or 2% EAFR was surely effective to reduce bacterial growth (Figure 2b), further maintaining the notion that inhibition of bacterial growth is vital in order to achieve improved host survivorship during infection.

3.4. Anti-Staphylococcal Activity of Roselle Fractions was Achieved Independent of Drosomycin Expression

Drosophila expressed an array of antimicrobial peptides (AMPs), including the well-characterized Drosomycin, that plays an important role in the innate immune response against *S. aureus*. To determine the involvement of Drosomycin expression in the antibacterial activity of WFR and EAFR against *S. aureus*,

Figure 2. Increased fly survivorship and impaired bacterial proliferation in infected flies given either WFR or EAFR. Adult 4-7 days old male *w^1118* were pricked with *S. aureus* and maintained at 25°C in food containing samples at two different concentrations (0.5 and 2%). These flies were subjected to survival assay (a) and analysis of bacterial growth (b). Groups of flies infected with *S. aureus* and maintained in the presence or absence of 200 μg/ml tetracycline were used as the negative and positive control groups, respectively. EER: ethanolic extract of roselle calyx, WFR: water fractions of rosella calyx extract, EAFR: ethyl acetate fractions of rosella calyx extract

we carried out two experimental approaches: *in vitro* and *in vivo*. In the *in vitro* experiment, we assessed Toll pathway-mediated Drosomycin expression by using cell-based reporter assay. We found that the expression of Drosomycin was not increased upon treatment with either WFR or EAFR (Figure 3a). In conjunction with the *in vitro* result, we also assessed the expression level of Drosomycin by RT-qPCR method using lysates

prepared from adult *w^1118* flies. As shown in Figure 3b, *Drosomycin (Drs)* expression was considerably induced in response to *S. aureus* infection and a comparable level of gene expression was similarly observed in other fly groups: the control groups (tetracycline-treated or 5% roselle calyx extract-treated), WFR-treated, and EAFR-treated *S. aureus*-infected fly groups. Moreover, level of *Drs* expression in all groups of treatments was not significantly different, clearly indicating that treatments given to the infected flies, either antibiotics, 5% roselle extract, 2% WFR, or 2% EAFR, did not increase the expression of *Drs* thus had no effect on the stimulation of *Drs*-related innate immune response in the *S. aureus*-infected host.

3.5. Protective Effect of Roselle Fractions in the *S. aureus*-infected Immunodeficient Host

Increased fly survivorship and reduced bacterial load were two trends observed in groups of *S. aureus*-infected flies that were incubated in the presence of roselle fractions, WFR or EAFR. These two protection signatures were achieved by mechanisms independent of Drosomycin, one of the most important AMPs expressed by *Drosophila* in response to *S. aureus* infection. Therefore, we anticipated that the anti-staphylococcal effect of WFR and EAFR might be resulted from the presence of selected antibacterial compounds available at a certain concentration in the roselle fractions tested in this study. To confirm this, we carried out pricking-based infection experiments on the *psh[1];;modSP[KO]*, a fly line lacking for Psh and ModSP, two important components in the canonical Toll-mediated antibacterial immune response against *S. aureus*. As illustrated in Figure 4, the survival of *psh[1];;modSP[KO]* mutant flies was declined in a faster rate (Figure 4a) and infected immunodeficient mutant flies harbored slightly higher bacterial load (Figure 4b) than its wild-type counterpart (Figure 2a and b, respectively), indicating the vital role of Psh and/or ModSP in the canonical Toll-mediated immune response against *S. aureus* infection. Nonetheless, it is important to note that two protection signatures: improvement of mutant flies' survivorship (Figure 4a) and reduction of bacterial growth (Figure 4b) were evident in the groups of infected mutant flies upon treatment with either 2% WFR or 2% EAFR. Taken together, our results confirmed the *in vivo* anti-staphylococcal activity of 2% WFR and 2% EAFR in the wildtype and immunodeficient *Drosophila* infection model.

Figure 3. Anti-staphylococcal protection of either WFR or EAFR was not due to stimulation in host humoral immunity. (a) Drs-Luc-DL1 cell line was treated with samples at different concentrations and subsequently assessed for its Drs level based on luciferase activity (p<0.001). (b) Adult 4-7 days old male w^{1118} were pricked with *S. aureus* and maintained at 25°C in food containing samples at given concentrations. These flies were subjected to total RNA isolation and subsequently followed by RT-qPCR for quantification of Drosomycin mRNA level. The expression level of *rp49* was used as the reference control (p<0.001). EER: ethanolic extract of roselle calyx, WFR: water fractions of rosella calyx extract, EAFR: ethyl acetate fractions of rosella calyx extract

Figure 4. Improved host survivorship and decreased bacterial growth in infected immunodeficient *psh[1];;modSP[KO]* flies in the presence of WFR or EAFR. Adult 4-7 days old male *psh[1];;modSP[KO]* flies were pricked with *S. aureus* and maintained at 25°C in food containing either water or ethyl acetate fractions of roselle extract. These flies were subsequently subjected to survival assay (a) and analysis of bacterial growth (b). Groups of flies infected with *S. aureus* and maintained in the presence or absence of 200 µg/ml tetracycline were used as the negative and positive control groups, respectively. EER: ethanolic extract of roselle calyx, WFR: water fractions of rosella calyx extract, EAFR: ethyl acetate fractions of rosella calyx extract

4. Discussion

Fruit fly *D. melanogaster* has been widely used to investigate cellular and molecular events that are relatively difficult to be addressed in higher model organisms (Pandey and Nichols 2011; Ugur *et al.* 2016; Nainu *et al.* 2017; Rahmatika *et al.* 2019). In fact, in the last decade, low- to high-throughput drug discovery using *D. melanogaster* platform has been widely performed (Willoughby *et al.* 2013; Fernández-Hernández *et al.* 2016; Ekowati *et al.* 2017),

and interestingly, one drug (Vandetanib, ZD6474) was successfully approved by US FDA for the treatment of medullary thyroid carcinoma in 2011 (Das and Cagan 2013).

In this study, we examined the antibacterial effect of two roselle fractions, WFR and EAFR, against *S. aureus* using a simple yet robust *in vitro* and *in vivo* pharmacological approach based on the use of *D. melanogaster*. A major advantage of our *in vivo* approach is the applicability of several important assays that are time-consuming or difficult to be performed using vertebrate model organisms. In terms of infection experiment, some of the experimental features such as simplicity of host survival assessment during the course of infection, easiness to perform colony-forming assay or gene expression analysis using whole-body samples or in the particular sites of infected tissues, and more importantly, broad availability of various ready-to-use lines of immunodeficient fruit flies, remain impressive powerful traits to be signified in *Drosophila* model of infection (Chamilos *et al.* 2011; Tzelepis *et al.* 2013).

The antibacterial effect of roselle fractions, WFR and EAFR, against *S. aureus* infection in *Drosophila* is likely to be achieved independent from additional participation of canonical Toll-mediated innate immune response in the infected host, as suggested by results obtained from *psh[1];;modSP[KO]* fly line that was used as immunodeficient *Drosophila* model. In the absence of two important components of Toll pathway, Psh and ModSP, stimulation of humoral innate immunity in response to *S. aureus* infection in *Drosophila* (i.e. the expression of AMPs) are impaired thus leads to an immunodeficient-like state (Buchon *et al.* 2014). Flies with such state has been shown to succumb faster during pathogen challenge than their wild-type counterparts (El Chamy *et al.* 2008; Buchon *et al.* 2009). However, in our study, we demonstrated that ingestion of either WFR or EAFR could improve the survivorship of infected *psh[1];;modSP[KO]* fly line, suggesting the anti-staphylococcal nature of roselle fractions.

Prior to infection experiments, we carried out toxicity assays using either cell cultures (*in vitro*) or adult flies (*in vivo*). Data obtained in these straightforward and time-effective assays suggested the toxicity of both roselle fractions was yielded in a manner dependent on the given dose of samples. Such results were important to decide the proper dose of

roselle fractions to be used in the next experiments and to rule out the possible toxic effect of samples to host survival during infection experiments.

In this research, we extended our previous results to demonstrate the *in vivo* anti-staphylococcal effect of fractions prepared from ethanolic extract of roselle calyx using a *Drosophila* platform system. While our *in vitro* and *in vivo* results were in line, it is important to note that *in vivo* testing of drug candidate(s) could provide better insight than the *in vitro* results in terms of potential efficacy as well as possible harmful effect of drug candidate(s) to individuals, especially in the case where the tested compound(s) are pro-drug. Hence, the use of inexpensive *in vivo* model organism, such as *D. melanogaster* (Pandey and Nichols 2011), that bids a high chance for getting similar outcomes in the clinical trial on human subjects could be a feasible option to improve our traditional drug discovery pipeline.

Conflict of Interest

We declare that we have no conflict of interest.

Acknowledgements

References

Ahsan M *et al.* 2019. *In vivo* anti-staphylococcal activity of roselle (*Hibiscus sabdariffa* L.) calyx extract in *Drosophila* model of infection, *J HerbMed Pharmacol* 8:41–46.

Alaga TO *et al.* 2014. Phytochemical and in vitro anti-bacterial properties of *Hibiscus sabdariffa* L (Roselle) juice. *J Med Plant Res* 8:339-344.

Buchon N *et al.*. 2009. A single modular serine protease integrates signals from pattern-recognition receptors upstream of the *Drosophila* Toll pathway. *Proc Natl Acad Sci USA* 106:12442-12447.

Buchon N *et al.*. 2014. Immunity in *Drosophila melanogaster*-from microbial recognition to whole-organism physiology. *Nat Rev Immunol* 14:796-810.

Chamilos G *et al.* 2011. *Drosophila* melanogaster as a model host for the study of microbial pathogenicity and the discovery of novel antimicrobial compounds. *Curr Pharm Des* 17:1246-1253.

Das TK, Cagan R. 2013. A *Drosophila* approach to thyroid cancer therapeutics. *Drug Discov Today Technol* 10:65-71.

El Chamy L *et al.*. 2008. Sensing of 'danger signals' and pathogen-associated molecular patterns defines binary signaling pathways 'upstream' of Toll. *Nat Immunol* 9:1165-1170.

Ekowati H *et al.* 2017. Protective effects of *Phaseolus vulgaris* lectin against viral infection in *Drosophila*. *Drug Discov Ther* 11:329-335.

Fernández-Hernández I *et al.* 2016. The translational relevance of *Drosophila* in drug discovery. *EMBO rep* 17:471-472.

García-Lara J *et al.* 2005. Invertebrates as animal models for *Staphylococcus aureus* pathogenesis: a window into host–pathogen interaction. *FEMS Immunol Med Microbiol* 43:311–323.

Gelband H *et al.* 2015. *The state of the world's antibiotics 2015. The Center for Disease Dynamics, Economics and Policy.* Washington: CDDEP.

Hassoun A *et al.* 2017. Incidence, prevalence, and management of MRSA bacteremia across patient populations—a review of recent developments in MRSA management and treatment. *Crit Care* 21:211.

Kanoh H *et al.* 2015. *Ex vivo* genome-wide RNAi screening of the *Drosophila* Toll signaling pathway elicited by a larva-derived tissue extract. *Biochem Biophys Res Commun* 467:400-406.

Levy SB, Marshall B. 2004. Antibacterial resistance worldwide: causes, challenges and responses. *Nat Med* 10:122-129.

Lewis K. 2013. Platforms for antibiotic discovery. *Nat Rev Drug Discov* 12:371-387.

Liu KS *et al.* 2005. *In vitro* antibacterial activity of roselle calyx and protocatechuic acid. *Phytother Res* 19:942-945.

Nainu F *et al.* 2017. Induction of apoptosis and subsequent phagocytosis of virus-infected cells as an antiviral mechanism. *Front Immunol* 8:1-11.

Nainu F *et al.* 2018. *In vivo* antibacterial activity of green algae *Ulva reticulata* against *Staphylococcus aureus* in *Drosophila* model of infection. *Pharmacog J* 10:993-997.

Nainu F *et al.* 2019. Protective effect of green algae *Ulva reticulata* against *Pseudomonas aeruginosa* in *Drosophila* infection model. *HAYATI J Biosci* 26:163-171.

Needham AJ *et al.* 2004. *Drosophila melanogaster* as a model host for *Staphylococcus aureus* infection. *Microbiol* 150:2347-2355.

Pandey UB, Nichols CD. 2011. Human disease models in *Drosophila melanogaster* and the role of the fly in therapeutic drug discovery. *Pharmacol Rev* 63:411-436.

Rahmatika D *et al.* 2019. Inhibitory effects of viral infection on cancer development. *Virology* 528:48-53.

Tong SYC *et al.* 2015. *Staphylococcus aureus* infections: Epidemiology, pathophysiology, clinical manifestations, and management. *Clin Microbiol Rev*. 28:603-661.

Tzelepis I *et al.* 2013 *Drosophila melanogaster*: a first step and a stepping-stone to anti-infectives. *Curr Opin Pharmacol*. 13:763-768.

Ugur B *et al.* 2016. *Drosophila* tools and assays for the study of human diseases. *Dis Mod Mech* 9:235-244.

Willoughby LF *et al.* 2013. An *in vivo* large-scale chemical screening platform using *Drosophila* for anti-cancer drug discovery. *Dis Mod Mech* 6:521-529.

Wright GD. 2014. Something old, something new: revisiting natural products in antibiotic drug discovery. *Can J Microbiol* 60:147-154.

Wu K *et al.* 2012. Assessment of virulence diversity of methicillin-resistant *Staphylococcus aureus* strains with a *Drosophila melanogaster* infection model. *BMC Microbiol* 12:274.